Syndax Pharmaceuticals Inc (SNDX) insider trading
Every open-market stock purchase and sale by Syndax Pharmaceuticals Inc executives, directors, large shareholders and members of Congress, from SEC Form 4 filings. Sector: Other.
Insider activity at a glance
- Insiders sold $2.7M over the last 12 months (8 sales). No open-market buys.
- Last insider buy: Keith Katkin (Insider), $91.1K, 17 months ago.
Last 12 months: insiders bought $0 (0 buys) and sold $2.7M (8 sales). Last close $13.15 on Oct 21, 2026.
Recent SNDX insider trades
| Date | Insider | Trade | Value |
|---|---|---|---|
| Jul 8, 2026 | Michael A Metzger (CEO) | Sold | $785K |
| Jul 8, 2026 | Michael A Metzger (CEO) | Bought (not open market) | $207K |
| Jul 8, 2026 | Michael A Metzger (CEO) | Bought (not open market) | — |
| Jun 12, 2026 | Nicholas A.J. Botwood (C-suite exec) | Sold | $567K |
| Jun 12, 2026 | Nicholas A.J. Botwood (C-suite exec) | Bought (not open market) | — |
| Jun 11, 2026 | Nicholas A.J. Botwood (C-suite exec) | Sold | $617K |
| Jun 11, 2026 | Nicholas A.J. Botwood (C-suite exec) | Bought (not open market) | — |
| Jun 1, 2026 | Michael A Metzger (CEO) | Sold | $130K |
| Jun 1, 2026 | Keith A. Goldan (CFO) | Sold | $22.4K |
| Feb 9, 2026 | Michael A Metzger (CEO) | Sold | $361K |
| Feb 9, 2026 | Keith A. Goldan (CFO) | Sold | $71.7K |
| Feb 6, 2026 | Michael A Metzger (CEO) | Sold | $153K |
| Feb 6, 2026 | Keith A. Goldan (CFO) | Sold | $42.9K |
| Feb 4, 2026 | Michael A Metzger (CEO) | Bought (not open market) | $9M |
| Feb 4, 2026 | Nicholas A.J. Botwood (C-suite exec) | Bought (not open market) | $3M |
| Feb 4, 2026 | Keith A. Goldan (CFO) | Bought (not open market) | $2.4M |
| Feb 4, 2026 | Keith A. Goldan (CFO) | Bought (not open market) | — |
| Feb 4, 2026 | Keith Katkin (Insider) | Bought (not open market) | — |
| Feb 4, 2026 | Dennis Podlesak (Insider) | Bought (not open market) | — |
| Feb 4, 2026 | Aleksandra Rizo (Insider) | Bought (not open market) | — |
| Feb 4, 2026 | Michael A Metzger (CEO) | Bought (not open market) | — |
| Feb 4, 2026 | Nicholas A.J. Botwood (C-suite exec) | Bought (not open market) | — |
| Feb 4, 2026 | Nicholas A.J. Botwood (C-suite exec) | Bought (not open market) | — |
| Feb 4, 2026 | Keith A. Goldan (CFO) | Bought (not open market) | — |
| Feb 4, 2026 | Martin H. Huber Jr. (Insider) | Bought (not open market) | — |
Who's trading SNDX
- Michael A Metzger, CEO: sold $1.4M (4 sales), last Jul 8, 2026
- Nicholas A.J. Botwood, C-suite exec: sold $1.2M (2 sales), last Jun 12, 2026
- Keith A. Goldan, CFO: sold $137K (3 sales), last Jun 1, 2026
- Keith Katkin, Insider: other filings, last Feb 4, 2026
- Pierre Legault, Insider: other filings, last Feb 4, 2026
- Aleksandra Rizo, Insider: other filings, last Feb 4, 2026
- Martin H. Huber Jr., Insider: other filings, last Feb 4, 2026
- Jennifer Jarrett, Insider: other filings, last Feb 4, 2026
- Dennis Podlesak, Insider: other filings, last Feb 4, 2026
Get free alerts when an insider at Syndax Pharmaceuticals Inc files a new trade →